LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN SPAIN: A COST-EFFECTIVENESS ANALYSIS

被引：0
|
作者：
de Arellano Serna, Ramirez A. [1 ]
Mezquita-Raya, P. [2 ]
Vega-Hernandez, G. [3 ]
Wojcik, R. [4 ]
Schlueter, M. [4 ]
机构：
[1] Novo Nordisk, Madrid, Spain
[2] Hosp Torrecardenas, Almeria, Spain
[3] Novo Nordisk Ltd, Gatwick, England
[4] IMS Hlth, London, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB54
引用
收藏
页码：A674 / A674
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN THE UK
    Schlueter, M.
    Vega-Hernandez, G.
    Wojcik, R.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A675 - A675
  • [2] COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN IN THE TREATMENT OF TYPE-2 DIABETES MELLITUS IN SPAIN
    Capel, M.
    Pomares, E.
    Perez-Alcantara, F.
    Simon, S.
    [J]. VALUE IN HEALTH, 2020, 23 : S508 - S508
  • [3] Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
    Gabriela Vega-Hernandez
    Radek Wojcik
    Max Schlueter
    [J]. Diabetes Therapy, 2017, 8 : 513 - 530
  • [4] Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
    Vega-Hernandez, Gabriela
    Wojcik, Radek
    Schlueter, Max
    [J]. DIABETES THERAPY, 2017, 8 (03) : 513 - 530
  • [5] DAPAGLIFLOZIN VERSUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN COLOMBIA: COST-EFFECTIVENESS ANALYSIS
    Ordonez, J. E.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A172 - A172
  • [6] THE COST-EFFECTIVENESS OF DULAGLUTIDE VERSUS LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TAIWAN
    Lin, H.
    Babineaux, S.
    Lew, T.
    Lowin, J.
    Lovato, E.
    Strizek, A. A.
    Rajan, N.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A898 - A898
  • [7] COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN VERSUS GLIMEPIRIDE AS MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CHINA
    Shao, H.
    Shi, L.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A898 - A898
  • [8] INCRETIN THERAPY FOR PATIENTS WITH TYPE 2 DIABETES IN SPAIN: A COST-EFFECTIVENESS ANALYSIS OF LIRAGLUTIDE VERSUS SITAGLIPTIN
    Ramirez de Arellano, A.
    Hunt, B.
    Mezquita Raya, P.
    Briones, T.
    Perez, A.
    Valentine, W. J.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A439 - A439
  • [9] COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN PERU
    Elgart, J. F.
    Gonzalez, L.
    Prestes, M.
    Manrique, H.
    Solorzano, J.
    Gagliardino, J. J.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A203 - A203
  • [10] Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin
    Pedro Mezquita Raya
    Antonio Pérez
    Antonio Ramírez de Arellano
    Teresa Briones
    Barnaby Hunt
    William J. Valentine
    [J]. Diabetes Therapy, 2013, 4 : 417 - 430
12345